Intellia Therapeutics, a leading biotechnology company, has recently been granted orphan drug designation by the European Commission for their investigational therapy, NTLA-2002. This therapy shows promise in the treatment of hereditary angioedema (HAE), a condition characterized by potentially life-threatening swelling attacks.
Positive Impact on Stock
Following this significant development, Intellia Therapeutics experienced a surge in their shares, with a 10% increase, reaching $26.10. This comes as a relief to the company, as their stock had hit a low point of $22.67 earlier this week, resulting in a 51% overall decrease in the past year.
Promising Research on NTLA-2002
NTLA-2002 is an innovative in vivo CRISPR-based therapy specially designed to prevent swelling attacks in individuals with HAE. This therapy has shown potential in combating this condition and offering hope to patients.
Orphan Drug Designation Process
In receiving orphan drug designation from the European Union, Intellia Therapeutics has successfully met the rigorous criteria set by the European Medicines Agency Committee for Orphan Medicinal Products. This designation is reserved for therapies intended to treat, prevent, or diagnose life-threatening or chronically debilitating diseases that affect a limited number of people in the EU population (not exceeding five in 10,000 individuals).
Recognition and Future Potential
Intellia Therapeutics’ NTLA-2002 has not only been granted orphan drug designation by the European Commission but has also received this prestigious recognition from the U.S. Food and Drug Administration. With five special regulatory designations already obtained for NTLA-2002, there is growing confidence in the therapeutic potential of this innovative solution.